Biography

Mr. Middleton has served as one of our directors since March 2018. He currently serves as a Managing Director of Sanderling Ventures, where he has worked for over 30 years as an investor, management team member and as a director in over 25 new biomedical ventures built in Sanderling’s venture investment portfolios since 1988. During his time at Sanderling, Mr. Middleton served as Vice Chairman and Chief Business Officer of Altor Biosciences, where he helped raise over $100M for clinical trials development and negotiated its subsequent acquisition by immunityBio, Inc. Mr. Middleton was an investor in Regeneron Pharmaceuticals and served as a board member and as the company’s CFO during its initial public offering in 1991. Earlier in his career, Mr. Middleton served as the third original member of the Genentech management team as its Chief Financial Officer from 1978-2004, completing its IPO in 1980. Mr. Middleton currently serves on the Boards of Directors for Viacyte, Inc., Calcimedica, Inc., and TheraVida, Inc., all privately held companies. Mr. Middleton holds a B.S. in chemistry from the Massachusetts Institute of Technology and an MBA with Distinction from the Harvard Business School.